Deuterated tryptamine derivatives and methods of use
AssigneeCybin IRL Limited
InventorsAlex Nivorozhkin, Michael Palfreyman
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
Claims18
A method of treating generalized anxiety disorder (GAD) in a subject, comprising administering to the subject a therapeutically effective amount of a compound, which is:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
A method of treating major depressive disorder (MDD) and/or treatment-resistant depression (TRD) in a subject, comprising administering to the subject a therapeutically effective amount of a compound, which is:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
A method of treating a bipolar disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound, which is:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
A method of treating a substance use disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound, which is:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
Dependencies are inferred from the claim text.